Inflammatory serum markers in patients with multiple trauma. Can they predict outcome?

Journal of Bone and Joint Surgery - Series B

Volumn 86, Issue 3, 2004, Pages 313-323

  Giannoudis, P V ^a   Hildebrand, F ^b   Pape, H C ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BASE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CD11B ANTIGEN; CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; CYTOKINE RECEPTOR; DNA; ELASTASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HLA DR ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; LACTIC ACID; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; LYMPHOTOXIN; PROCALCITONIN; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ALKALOSIS; BLUNT TRAUMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; GLASGOW COMA SCALE; HEALTH CARE COST; HUMAN; HYPERLACTATEMIA; IMMUNOBIOLOGY; IMMUNOREACTIVITY; MEDIATOR; MEDICAL PARAMETERS; MICROENVIRONMENT; MORBIDITY; MORTALITY; MULTIPLE TRAUMA; MUSCULOSKELETAL SYSTEM INFLAMMATION; NEUTROPHIL; NONHUMAN; ORTHOPEDIC SURGERY; PATHOPHYSIOLOGY; PENETRATING TRAUMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; SURGICAL INJURY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CALCITONIN; CARRIER PROTEINS; CELL ADHESION MOLECULES; HLA-DR2 ANTIGEN; HUMANS; INFLAMMATION; INTERLEUKINS; MEMBRANE GLYCOPROTEINS; MULTIPLE ORGAN FAILURE; PANCREATIC ELASTASE; PROTEIN PRECURSORS; RECEPTORS, CYTOKINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342446333     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.86B3.15035     Document Type: Review

References (138)

1. Regel G, Lobrnhoffer P, Grotz M, et al. Treatment results of patients with multiple trauma: an analysis of 3406 cases treated between 1972 and 1991 at a German level I center. J Trauma 1995;38:70-8.
2. Baue A. Multiple organ failure, multi organ dysfunction syndrome, and the systemic inflammatory response syndrome-where do we stand? Shock 1994;2:385-97.
3. Pape HC, Stalp M, van Griensven M, et al. Optimal timing for secondary surgery in polytrauma patients: an evaluation of 4314 serious-injury cases. Chirurg 1999;70: 1287-93.
4. Mannikis P, Jankowski S, Zhang H, Kahn RJ, Vincent JL. Correlation of serial lactate levels to organ failure and mortality after trauma. Am J Emerg Med 1995;13: 619-22.
5. McNelis J, Marini CP, Jurkiewicz A, et al. Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit. Am J Surg 2001; 182:481-5.
6. Rixen D, Raum M, Bouillon B, et al. Predicting the outcome in severe injuries: an analysis of 2069 patients from the trauma register of the German Society of Traumatology(OGU). Unfallchirurg 2001;104:230-9.
7. Rixen D, Raum M, Bouillon B. et al. Base deficit development and its prognostic significance in post-trauma critical illness: an analysis by the trauma registry of the Deutsche Gesellschaft für Unfallchirirgie. Shock 2001;15:83-89.
8. Tremblay LN, Feliciano DV, Rozycki GS. Assessment of initial base deficit as a predictor of outcome: mechanism of injury does make a difference. Am J Surg 2002; 68:689-4.
9. Davis JW, Kaups KL. Base deficit in the elderly: a marker of severe injury and death. J Trauma 1998;45:873-7.
10. Giannoudis PV. Current concepts of the inflammatory response after major trauma: an update. Injury 2003;34:397-404.
11. Harlan JM. Neutrophil-mediated vascular injury. Acta Med Scand 1987;715 (Suppl): 123-9.
12. Varani J, Ward RA. Mechanisms of endothelial cell injury in acute inflammation. Shock 1994;2:311-9.
13. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662-75.
14. Smith RM, Giannoudis PV. Trauma and immune response. R Soc Med 1998;91: 417-20.
15. Giannoudis PV, Smith RM, Banks RE, et al. Stimulation of inflammatory markers after blunt trauma. Br J Surg 1998;85:986-90.
16. Cipolle MD, Pasquale MD, Cerra FB. Secondary organ dysfunction: from clinical perspectives to molecular mediators. Crit Care Clin 1993;9:261-97.
17. Anderson BO, Harken AH. Multiple organ failure: inflammatory priming and activation sequences promote autogenous tissue injury. J Trauma 1990;30 (Suppl):44-7.
18. Giannoudis PV, Smith RM, Ramsden CW, et al. Molecular mediators and trauma: effects of accidental trauma on the production of plasma elastase, IL-6, sICAM-1 and sE-selectin. Injury 1996;27:376-7.
19. Giannoudis PV, Pape HC, Cohen A, Kretteck C, Smith RM. Systemic effects of femoral nailing: from Kuntcher to the immune reactivity era. Clin Orthop 2002;404: 378-86.
20. Maekawa K, Futami S, Nishida M, et al. Effects of trauma and sepsis on soluble L-selectin and cell surface expression of L-selectin and CD11b. J Trauma 1998:44: 460-8.
21. Pape HC, Schmidt RE, Rice J, et al. Biochemical changes following trauma and skeletal surgery of the lower extremity: quantification of the operative burden. Crit Care Med 2000;28:3441-8.
22. Schumann RR, Leong SR, Flagge GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990;249:1429-3.
23. Lamping N, Detmer R, Schroder N, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998;101:2065-71.
24. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001;98:3800-8.
25. Sablotzki A, Borgermann J, Bauling W, et al. Lipopolysaccharide-binding protein (LBP) and markers of acute phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac Cardiovasc Surg 2001; 49:273-8.
26. Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999,180:1584-9.
27. Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis 2003;187:287-91.
28. Whicher JT, Evans SW. Acute phase proteins. Hosp Update 1990:899-905.
29. Mimoz O, Benoist JF, Edouard AR, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998;24:185-8.
30. Gosling P, Dickson GR. Serum C-reactive protein in patients with serious trauma. Injury 1992;23:483-86.
31. Pernaby RM, Eaton SE, Shafi MS, Bell D. The value of serum C-reactive protein levels as a marker of sepsis in intensive care unit patients. Clin Intensive Care 1994; 5:106-13.
32. Monneret G, Laroche B, Bienven J. Procalcitonin is not produced by circulating blood cells. Infection 1999;27:34-5.
33. Wanner GA, Keel M, Steckholzer U, et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000;28:950-7.
34. Oberholzer A, Keel M, Zellweger R, et al. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. J Trauma 2000;48: 932-7.
35. Oberhoffer M, Karzai W, Meier-Hellmann A, et al. Sensitivity and specificity of various markers of inflammation for the prediction of tumour necrosis alpha and interleukin-6 in patients with sepsis. Crit Care Med 1999;27:1814-8.
36. Benoist JF, Mimoz O, Assicot M, Edouard A. Serum procalcitonin, but not C-reactive protein, identifies sepsis in trauma patients. Clin Chem 1998;44:1778-9.
37. Cheval C, Timsit JF, Garrouste-Oregas M, et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Intensive Care Med 2000;26:S153-8.
38. Molter GP, Soltesz S, Kottke R, et al. Procalcitonin plasma concentrations and systemic inflammatory response following different types of surgery. Anaethesist 2003:52:210-7.
39. Stiletto RJ, Baacke M, Gotzen L. Lefering R, Renz H. Procalcitonin versus interleukin-6 levels in bronchoalveolar lavage fluids of trauma victims with severe lung contusion. Crit Care Med 2001;29:1690-3.
40. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med 1993;21 (Suppl):415-2.
41. Okusawa S, Yancey KB, van der Mer JWM, et al. C5a stimulated secretion of tumour necrosis factor from human mononuclear cells in vitro: comparison with secretion of interleukin 1β interleukin 1α. J Exp Med 1988;168:443-8.
42. van Griensven M, Stalp M, Seekamp A. Ischemia-reperfusion directly increases pulmonary permeability in vitro. Shock 1999;11:259-63.
43. Dofferhoff ASM, Bom VJJ, do Vrie-Hosper HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
44. Riche F, Pani Y, Laisne M, et al. High tumor necrosis factor serum Ilevel is associated with increased survival in patients with abdominal septic shock: a prospective study in 59 patients. Surgery 1996;120:801-7.
45. Arditi M, Manoque KR, Caplan M, Yoger R. Cerebrospinal fluid cachectin/tumour necrosis factor alpha and platelet-activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis 1990;160:139-47.
46. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Inter Med 1993;119:771-8.
47. Meduri GU, Kohler G, Headley S, et al. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 1995;108:1303-14.
48. Beutler B, Cerami A. Cachetin: more than a tumor necrosis factor. N Engl J Med 1987;316:379-85.
49. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4.
50. Exley AR, Cohen J, Buurmann W, et al. Monoclonal antibodies to TNF in severe septic shock. Lancet 1990;335:1275-7.
51. Bertini R, Delgado R, Faggioni R, et al. Urinary TNF binding protein (TNF soluble receptor) protects mice against the lethal effects of TNF and endotoxin shock. Eur Cytokine Netw 1993;4:39-42.
52. Angele MK, Xu YX, Ayala A, et al. Gender dimorphism in trauma-hemorrhage-induced thymocyte apoptosis. Shock 1999;12:316-22.
53. Riche FC, Cholley BF, Panis YH, et al. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000;28:433-7.
54. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple system organ failure and mortality. Chest 1993;103: 565-75.
55. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1 receptor antagonist circulated in experiemental endotoxaemia. Lancet 1991;338:1423-4.
56. Fisher E, Van Zee KJ, Marano MA, et al. IL-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992;79:2196-200.
57. Fisher E, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant IL-1 receptor antagonist in the treatment of patients with sepsis syndrome: a randomised open label, placebo controlled multicenter trial. Crit Care Med 1994;22: 12-21.
58. Fisher CJ Jr, Dhainault JF, Opal SM, et al. Recombinant human IL-1 receptor antagonist in the treatment of patients with sepsis syndrome: results of a randomised double bind placebo controlled trial. Phase III rhIL-1Ra Sepsis Study Group. JAMA 1994;27:1836-43.
59. Le J, Vilcek J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-602.
60. Gabhard F, Pfetsch H, Steinbach G, et al. Is Interleukin-6 an early marker of injury severity following major trauma in humans. Arch Surg 2000;135:291-5.
61. Pape HC, van Griensven M, Rice J, et al. Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma 2001;50:989-1000.
62. Damas P, Ledoux D, Nys M, et al. Cytokine serum levels during sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215:356-62.
63. Hack GE, De Groot ER, Felt-Bersma RJ, et al. Increased levels of interleukin-6 in sepsis. Blood 1989;74:1704-10.
64. Meduri GU, Headley S, Kohler M, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062-73.
65. Dofferhoff ASM, Bom VJJ, de Vrier-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
66. Giannoudis PV, Smith RM, Evans RT, Bethany MC, Guillou PJ. Serum CRP and IL-6 levels after trauma: not predictive of septic complications. Acta Orthop Scand 1998;69:184-8.
67. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vriers JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
68. Mackay F, Rothe J, Bluethmann H, Letscher H, Lesslauer W. Differential responses of fibroblasts from wild-type and TNF-R55-deficient mice to mouse and human TNF-alpha activation. J Immunol 1994;153:5274-84.
69. Neidhardt TR, Keel M, Steckholzer U, et al. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997;42:863-70.
70. Giannoudis PV, Smith RM, Perry SL, et al. Immediate IL-10 expression following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development of sepsis. Intensive Care Med 2000;26:1076-81.
71. Smith RM, Giannoudis PV, Bellamy MC, et al. Interleukin-10 release and monocyte human leukocyte antigen-DR expression during femoral nailing. Clin Orthop 2000;373:233-40.
72. Merchant A, Deviere J, YI BB, et al. Interleukin-10 production during septicaemia. Lancet 1994;343:707-8.
73. Hensler T, Hecker, Heeg K, et al. Distinct mechanism of immunosuppression as a consequence of major surgery. Infect Immunol 1997;65:2283-91.
74. Miller-Graziano CL, De Kumar A, Kodys K. Altered IL-10 levels in trauma patients mø and T-lymphocytes. J Clin Immunol 1995; 15:94-104.
75. Lyons A, Goebel A, Mannick JA, Lederer JA. Protective effects of early interleukin 10 antagonism on injury-induced immune dysfunction. Arch Surg 1999;134: 1317-23.
76. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
77. Rongione AJ, Kusske AM, Ashley SW, Reber AH, McFadden DW. Interleukin-10 prevents early cytokine release in severe intraabdominal infection and sepsis. J Surg Res 1997;70:107-12.
78. Kato T, Murata A, Ipsida H, et al. Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother 1995;39:1336-40.
79. Remick DG, Garg SJ, Newcomb DE, et al. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 1998;26:895-904.
80. Song GY, Chung CS, Chaudry IH, Ayala A. What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunisuppressant: Surgery 1999;126: 378-83.
81. Hyodo Y, Matsui N, Hayashi E, et al. IL-19 up-regulates perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999; 162:1662-8.
82. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T-cells. Nature 1995:378:88-91.
83. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleulkin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-74.
84. Oberholzer A, Feilner A, Hentze H, et al. Sepsis after severe injury interrupts casepase-dependent processing of interleukin-18. J Trauma 2000;49:11-6.
85. Oberholzer A, Steckholzer U, Kurimoto M, Trentz O, Ertel W. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock 2001;16:411-4.
86. Emmanuilidid K, Weighardt H, Matevossian E, et al. Differential regulation of systemic IL-18 and IL-12 release during post-operative sepsis: high serum IL-18 as an early predictive indicator or lethal outcome. Shock 2002;18:301-5.
87. Sakao Y, Takeda K, Tsutsui H, et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Immunol 1999; 11:471-80.
88. Hochholzer P, Lipford GB, Wagner H, Pfeffer K, Heeg K. Role of interleukin-18 (IL-18) during lethal shock: decreased lipopolysaccharide sensitivity but normal super-antigen reaction in IL-18-deficient mice. Infection and Immunity 2000;68:3502-8.
89. Endo S, Inada K, Yamada Y, et al. Interleukin 18 (IL-18) levels in patients with sepsis. J Med 2000;31:15-20.
90. Krohn CD, Reikeras O, Aasen AO. The cytokines IL-1beta and II-1 receptor antagonist, II-2 and II-2 soluble receptor-α, II-6 and II-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL-10 in drained and systemic blood after major orthopaedic surgery. Eur J Surg 1999;165:101-9.
91. Pellegrini JD, Puyana JC, Lapchak PH, Kodys K, Müller-Graziono CL. A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock 1996; 6:389-96.
92. Spielmann S, Kerner T, Ahlers D, et al. Early detection of increased tumor necrosis factor alpha (TNF-α) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand 2000;45: 364-70.
93. Ribeiro CA, Andrade C, Polanczyk CA, Clausell N. Association between early detection of soluble TNF-receptors and mortality in burn patients. Intensive Care Med 2002;28:472-8.
94. Adam DJ, Lee AJ, Ruckley CV, Bradbury AW, Ross JA. Elevated levels of soluble tumor necrosis factor receptors are associated with increased mortality rates in patients who undergo operation for ruptured abdominal aortic aneurysm. J Vas Surg 2000;31:514-9.
95. Patrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Release of anti-inflammatory mediators after major torso trauma correlates with the development of post injury multiple organ failure. Am J Surg 1999;178:564-8.
96. Pruitt JH, Welborn MB, Edwards PD, et al. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 1996;87:3282-8.
97. Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 2002;89:1450-6.
98. Hans VHJ, Kossmann T, Joller H, Otto V, Morganti-Kossmann MC. Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuro Report 1999;10:409-12.
99. Hisani S, Sakamato K, Ishiko T, Kamohara H, Ogawa M. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field. Cytokine 1997;9:447-52.
100. Furie MB, Mchugh MM. Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. J Immunol 1989;143:3309-17.
101. Bargatze RF, Kurk S, Watts G, et al. In vivo and in vitro functional examination of a conserved epitope of L- and E-Selectin crucial for leukocyte-endothelial cell interactions. J Immunol 1994;152:5814-25.
102. Picker LJ, Warnock RA, Burns AR, et al. The neutrophil selectin LECAM-1 presents carbohydrate ligans to the vascular selectins ELAM-1 and GMP-40. Cell 1991:66:921-33.
103. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
104. Seekamp A, van Griensven M, Hildebrand F, et al. The effect of trauma on neutrophil L-selectin serum levels. Shock 2001;15:254-60.
105. Ramamoorthy C, Sharar SR, Harlan JM, Tedder TF, Winn RK. Blocking L-selectin function attenuates reperfusion injury following hemorrhagic shock in rabbits. Am J Physiol 1996;271:H1871-7.
106. Beatty PG, Ochs HD, Harland JM, et al. Absence of monoclonal-antibody-defined protein complex in boy with abnormal leucocyte function. Lancet 1994;1:535-7.
107. Doerschuk CM, Winn RK, Coxson HO, Harlam JM. CD18-dependent and -independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits. J Immunol 1990;144:2327-33.
108. Seekamp A, Mulligan MS, Till GO, et al. Role of beta2-integrins and ICAM-1 in lung injury following ischemia-reperfusion of rat hind limbs. Am J Pathol 1993;143:452-63.
109. Vedder NB, Fouty BW, Winn RK, Harlan JM, Rice CL. Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock. Surgery 1989; 106:509-16.
110. Essani NA, Fisher MA, Farhood A, et al. Cytokine-induced upregulation of hepatic intercellular adhesion molecule-1 messenger RNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. Hepatology 1995; 21:1632-9.
111. Simms HH, D'Amico R. Increased PMN CD11b/CD18 expression following post-traumatic ARDS. J Surg Res 1991;50:362-7.
112. Law MM, Cryer HG, Abraham E. Elevated levels of soluble ICAM-1 correlate with the development of multiple organ failure in severely injured trauma patients. J Trauma 1994;37:100-9.
113. Tsokos M, Fehlauer F. Post-mortem markers of sepsis: an immunohistochemical study using VLA-4 (CD49d/CD29) and ICAM-1 (CD54) for the detection of sepsis-induced lung injury. Int J Legal Med 2001;114:291-4.
114. Whalem MJ, Doughty LA, Carlos TM, et al. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 are increased in the plasma of children with sepsis-induced multiple organ failure. Crit Care Med 2000;28:2600-7.
115. van den Engel NK, Heidenthal E, Vinke A, Kolb H, Martin S. Circulating forms of intercellular adhesion molecule (ICAM)-1 in mice lacking membranous IVCAM-1. Blood 2000;95:1350-5.
116. Anderson BO, Brown JM, Harken AH. Mechanisms of neutropil-mediated tissue injury. J Surg Res 1991;51:170-9.
117. Takahashi H, Nukiwa T, Basset P, Crystal RG. Myelomonocytic cell lineage expression of the neutrophil elastase gene. J Biol Chem 1988;263:2543-7.
118. Bedard M, McClure CD, Schiller NL, et al. Release of IL-8, IL-6, and colony stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol 1993;9:455-62.
119. du Bois RM, Beranudin JF, Paakko P, et al. Human neutrophils express the alpha 1-antitrypsin gene and product alpha1-antitrypsin. Blood 1991;77:2724-30.
120. Gordon MW, Robertson CE, Dawes J. Neutrophil elastase levels and major trauma in man. Int Care Med 1992;15:543-8.
121. Jochum M, Fritz H. Pathobiochemical mechanisms in inflammation. In: Faist E, Ninnemann JL, Green DR, eds. Immune consequences of trauma shock and sepsis. Berlin: Springer 1989;165-72.
122. Nuytinck JKS, Goris JA, Redl H, Schlag G, van Munster PJ. Post-traumatic complications and inflammatory mediators. Arch Surg 1986;121:886-90.
123. Donnelly SC, MacGregor I, Zamani A, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med 1995;151:1428-33.
124. Tonz M, Mihajevic T, von Sagesser, et al. Acute lung injury during cardiopulmonary bypass: are the neutrophils responsible? Chest 1995;108:1551-6.
125. Ayala A, Ertel W, Chaudry IH. Trauma induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock 1996;5:79-90.
126. Hershman MJ, Cheadle WG, Wellhousen SR, et al. Monocyte HLA-Dr antigen expression characteristics clinical outcome in the trauma patients. Br J Surg 1990;77: 204-7.
127. Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T-cells of patients developing infection after surgery. Br J Surg 1993;80:205-9.
128. Ditschkowski M, Kreuzfelder E, Rebmann V, et al. HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 1999;229:246-54.
129. Cheadle EG, Hershman MJ, Wellhausen SR, Polk HC Jr. HLA-Dr antigen expression on peripheral blood monocytes correlated with surgical infection. Am J Surg 1991;161:639-45.
130. Gibbons RA, Martinez OM, Lim R, et al. Reduction in HLA-Dr, HLA-DQ and HLA-DP expression my Leu-M3+ cells from the peripheral blood of patients with thermal injury. Clin Exp Immunol 1989;75:371-5.
131. Giannoudis PV, Smith RM, Windsor AC, Bellamy MC, Guillou PJ. Monocyte human leukocyte antigen-DR expression correlates with intrapulmonary shunting after major trauma. Am J Surg 1999;177:454-9.
132. Rainer TH. Plasma DNA, prediction and post-traumatic complications. Clin Chim Acta 2001;13:81-5.
133. Rainer TH, Lo YM, Chan LY, et al. Derivation of a prediction rule of posttraumatic organ failure using plasma DNA and other variables. Ann N Y Acad Sci 2001;945:211-20.
134. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319-23.
135. Fowler AA, Hammon RF, Good JT, et al. Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med 1983:98:593-7.
136. Cain BS, Meldrum DR, Harken AH, McIntyre TC Jr. The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg 1998:186: 337-50.
137. Abraham E, Glauser MP, Butler T, et al. P55 tumor necrosis factor receptor fusion protein in the treatment of patient with severe sepsis and septic shock: a randomised controlled multicenter trial: RO 45-2081 Study Group. JAMA 1997;277: 1531-8.
138. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial: TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.